Identification of a specific systemic transcriptome able to differentiate patients with renal transplantation in chronic treatment with tacrolimus from those with mTOR inhibitors. - NA

概览

暂无简介。

注册库

who.int

开始日期

2014年2月19日

结束日期

待定

最后更新

11年前

研究类型

Interventional clinical trial of medicinal product

性别

All

发起方

•Written informed consent
•age \> 18 years
•first renal transplantation
•renal transplantation performed since more than 6 months at the time of enrollment
•estimated GFR (as assessed by the use of the equation aMDRD) greater than 30 mL / min
•Chronic treatment with tacrolimus or mTOR inhibitors (everolimus, sirolimus) in
•combination with mycophenolate mofetil (MMF) since more than 6 months
•Blood levels between 4\-8 ng/ml (Tacrolimus) and 4\-8 ug/L (inhibitors
•Chronic treatment with corticosteroid (prednisone 5 mg or 4 mg of methylprednisolone)
•Are the trial subjects under 18? no

•Patients participating in another study
•Change in GFR\> 30% in the 6 months prior to enrollment
•Diagnosis and treatment of acute rejection in the 6 months prior to enrollment
•other solid organ transplantation in combination with renal transplantation
•Malignant neoplasm in the active phase (excluding non\-melanoma skin cancer)
•Hemodialysis
•Severe acute and chronic liver disease (hepatitis B virus\-related, hepatitis C virus\-related, toxic,
•immunoallergic)
•Women with a positive pregnancy test at enrollment
•Pregnant or breastfeeding women or women not using effective contraception if